BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26617867)

  • 1. Prognostic significance of HOXD13 expression in human breast cancer.
    Zhong ZB; Shan M; Qian C; Liu T; Shi QY; Wang J; Liu Y; Liu Y; Huang YX; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):11407-13. PubMed ID: 26617867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXD13 methylation status is a prognostic indicator in breast cancer.
    Zhong Z; Shan M; Wang J; Liu T; Xia B; Niu M; Ren Y; Pang D
    Int J Clin Exp Pathol; 2015; 8(9):10716-24. PubMed ID: 26617782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological significance of ARID1B in breast invasive ductal carcinoma.
    Shao F; Guo T; Chua PJ; Tang L; Thike AA; Tan PH; Bay BH; Baeg GH
    Histopathology; 2015 Nov; 67(5):709-18. PubMed ID: 25817822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma.
    Zhao P; Lu Y; Jiang X; Li X
    Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LETM1 overexpression is correlated with the clinical features and survival outcome of breast cancer.
    Li N; Zheng Y; Xuan C; Lin Z; Piao L; Liu S
    Int J Clin Exp Pathol; 2015; 8(10):12893-900. PubMed ID: 26722481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of MAGE-A9 predicts unfavorable outcome in breast cancer.
    Xu X; Tang X; Lu M; Tang Q; Zhang H; Zhu H; Xu N; Zhang D; Xiong L; Mao Y; Zhu J
    Exp Mol Pathol; 2014 Dec; 97(3):579-84. PubMed ID: 25445503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients.
    Tang J; Deng R; Luo RZ; Shen GP; Cai MY; Du ZM; Jiang S; Yang MT; Fu JH; Zhu XF
    Breast Cancer Res Treat; 2012 Jul; 134(2):549-60. PubMed ID: 22585231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
    Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
    BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.
    Cao YW; Li WQ; Wan GX; Li YX; Du XM; Li YC; Li F
    J Exp Clin Cancer Res; 2014 Nov; 33(1):97. PubMed ID: 25420528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast.
    Buhmeida A; Dallol A; Merdad A; Al-Maghrabi J; Gari MA; Abu-Elmagd MM; Chaudhary AG; Abuzenadah AM; Nedjadi T; Ermiah E; Al-Thubaity F; Al-Qahtani MH
    Tumour Biol; 2014 Mar; 35(3):2817-24. PubMed ID: 24248542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
    Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
    BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma.
    Davidson B; Valborg Reinertsen K; Trinh D; Reed W; Bøhler PJ
    Hum Pathol; 2016 Aug; 54():64-73. PubMed ID: 27038683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HOX D13 expression across 79 tumor tissue types.
    Cantile M; Franco R; Tschan A; Baumhoer D; Zlobec I; Schiavo G; Forte I; Bihl M; Liguori G; Botti G; Tornillo L; Karamitopoulou-Diamantis E; Terracciano L; Cillo C
    Int J Cancer; 2009 Oct; 125(7):1532-41. PubMed ID: 19488988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast.
    Qian L; Gao X; Huang H; Lu S; Cai Y; Hua Y; Liu Y; Zhang J
    Oncotarget; 2017 Mar; 8(13):21444-21453. PubMed ID: 28423522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node‑negative early breast cancer: 15-year follow-up.
    Donizy P; Pietrzyk G; Halon A; Kozyra C; Gansukh T; Lage H; Surowiak P; Matkowski R
    Oncol Rep; 2014 Apr; 31(4):1777-87. PubMed ID: 24535158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.
    Xiao J; Zhou Y; Zhu W
    Int J Clin Exp Pathol; 2015; 8(6):6458-65. PubMed ID: 26261522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
    Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
    Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ASMA
    Amornsupak K; Jamjuntra P; Warnnissorn M; O-Charoenrat P; Sa-Nguanraksa D; Thuwajit P; Eccles SA; Thuwajit C
    Clin Breast Cancer; 2017 Oct; 17(6):441-452.e2. PubMed ID: 28533055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Relation of Parafibromin Expression with Clinicopathological Factors in Invasive Breast Carcinomas.
    Karaarslan S; Genç B; Nart A; Börekçi İ; Buğdayci MH
    Turk Patoloji Derg; 2016; 32(1):8-14. PubMed ID: 26832176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.